BB 2827

Drug Profile

BB 2827

Latest Information Update: 09 Apr 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator British Biotech
  • Developer British Biotech; Merck Serono
  • Class Antirheumatics
  • Mechanism of Action Matrix metalloproteinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Periodontal disorders; Rheumatoid arthritis

Most Recent Events

  • 27 Jul 2001 Discontinued-I for Rheumatoid arthritis in Europe (PO)
  • 26 Jun 2001 Investigation in Periodontal disorders in Europe (PO)
  • 31 Oct 2000 Serono has an option to obtain exclusive rights to BB 2827
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top